论文部分内容阅读
随着1972年丁咪胺的合成,Black等证明组织胺受体有两类:H_1和H_2。H_2受体和H_1受体不同,它不为“典型”的或传统的抗组织胺所拮抗,并参与组织胺对胃的壁细胞作用。丁咪胺为第一种H_2受体拮抗剂,可选择地阻断组织胺刺激胃酸分泌,但口服无效。甲氰咪胺是第二种的H_2受体拮抗剂,美国和欧洲的研究所累积的许多资料,足够对此药在治疗消化性溃疡病和有关的酸性消化性疾病的临床效果以及应用方面作一评论。
With the synthesis of dmidemide in 1972, Black et al. Demonstrated two classes of histamine receptors: H_1 and H_2. H 2 receptors, unlike H 1 receptors, are not antagonized by “classic” or conventional antihistamines and are involved in the action of histamine on parietal cells of the stomach. Dimamine is the first H 2 receptor antagonist that selectively blocks histamine stimulating gastric acid secretion, but is orally ineffective. Cimetidine is the second H 2 receptor antagonist and many of the data accumulated in research in the United States and Europe are sufficient for the clinical efficacy and application of this drug in the treatment of peptic ulcer disease and related acidic digestive diseases A comment.